Key result
SGLT2 inhibitors linked to reduced atrial electromechanical delay and left atrial volume in T2D.
Why the study?
SGLT2 inhibitors are associated with lower AF incidence in DM, and this study evaluated changes in atrial electromechanical delay, an electrophysiological marker related to AF development, in type 2 DM patients treated with an SGLT2 inhibitor.
Does SGLT2 inhibitor therapy reduce atrial electromechanical delay in patients with type 2 diabetes?
Does SGLT2 inhibitor therapy reduce atrial electromechanical delay in patients with type 2 diabetes?
SGLT2 inhibitors significantly reduce atrial electromechanical delay and left atrial volume at 4 months in patients with type 2 diabetes, suggesting a potential mechanism for their protective effect against atrial fibrillation.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been associated with lower atrial fibrillation (AF) incidence in diabetes mellitus (DM). Atrial electromechanical delay (AEMD) is an electrophysiological marker related to AF development. This study evaluated AEMD changes in type 2 DM patients treated with an SGLT2 inhibitor (dapagliflozin or empagliflozin). Baseline and 4-month follow-up data of 50 patients with type 2 diabetes who initiated SGLT2 inhibitor therapy were retrospectively obtained from medical records and analyzed. AEMD was measured using echocardiography and tissue Doppler. Inter-AEMD and intra-AEMD intervals were calculated. Left atrial volume (LAVOL) significantly decreased (45.23 ± 9.27 vs 42.21 ± 9.16; P < .001), while left intra-AEMD (19.58 ± 7.53 vs 16.76 ± 7.53; P <.001), right intra-AEMD (14.42 ± 5.81 vs 12.46 ± 8.05; P = .016), and inter-AEMD (34 ± 9.41 vs 29.22 ± 9.44; P < .001) were significantly reduced. Inter-AEMD change correlated with LAVOL, E/E' ratio, body mass index, and mean blood pressure changes (all P <.05). In diabetic patients treated with SGLT2 inhibitors, AEMD reduction was observed after 4 months, with favorable metabolic and hemodynamic effects. These findings suggest that SGLT2 inhibitors may protect against AF by improving atrial electromechanical function.
No takes yet. Share an insight, caveat, or question.
Erzurum et al. (2026) studied this question. Treatment with SGLT2 inhibitors led to a significant reduction in atrial electromechanical delay and left atrial volume in patients with type 2 diabetes after 4 months (all P < .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: